Merck
FDA ask MSD to join blockchain supply chain network
June 14, 2019Medical Communications FDA, MSD, Merck, blockchain, supply chain
The FDA has asked MSD to join a shared permission blockchain network to help track and trace prescription medicines and …
FDA approves new indication for MSD’s Zerbaxa
June 5, 2019Research and Development Merck, Zerbaxa, bacterial infection, pharma
The FDA has approved US firm Merck’s Zerbaxa (ceftolozane and tazobactam) for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial …
Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer
June 3, 2019Sales and Marketing KEYNOTE, MSD, Merck, keytruda, lung cancer
Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to …
Top Ten most popular articles on Pharmafile.com this week!
March 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …
Merck KGaA enters drug discovery partnership with AI firm Itkos
March 15, 2019Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma
Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …
Top Ten most popular articles on Pharmafile.com this week!
February 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, GSK, Merck, Pfizer, falsified medicines, strike, top 10
The strike in Ireland featured twice in this week’s top 10 after Pfizer employees in County Cork lost a dispute …
GSK buys Merck KGaA’s cancer immunotherapy for $4.2 billion
February 6, 2019Research and Development GSK, M7824, Merck, immunotherapy
British multinational GlaxoSmithKline has agreed to pay up to €3.7 billion ($4.2 billion) for the rights to Merck KGaA’s next …
Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application
January 25, 2019Medical Communications BMS, Merck, Yervoy, ctla4, lung cancer, opdivo
Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer. …
Keytruda scores ground-breaking European approval in lung cancer subgroup
September 10, 2018Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma
Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …
MSD’s experimental vaccine to be used in fight against Congo Ebola outbreak
August 8, 2018Research and Development Congo, Ebola, MSD, Merck, Vaccine, pharma
MSD’s experimental drug rVSV-ZEBOV will be used in tackling the latest Ebola outbreak in the Democratic Republic of Congo, after …
Merck KGaA announces new Senior Vice President, Head of Global Affairs
July 26, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dr Maria Rivas, Germany, Merck, Merck KGaA, research and development
Merck KGaA has announced the appointment of Dr Maria Rivas as Senior Vice President, Head of Global Affairs. Dr Rivas, …
Merck joins Pizer and Novartis in reducing drug prices
July 20, 2018Medical Communications Merck, Novartis, Pfizer, Trump, Twitter, price hikes
Merck & Co. have joined Pfizer and Novartis in halting price increases on medicines in the United States. The American …
AstraZeneca’s Lynparza proves efficacy in first-line BRCA-mutated advanced ovarian cancer
June 27, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, Merck, ovarian cancer, pharma
AstraZeneca is celebrating alongside partner MSD with the reveal of new data on the use of Lynparza in the first-line …
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer
June 5, 2018Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …
NICE recommends MSD’s Keytruda for advanced PD-L1-positive lung cancer
June 5, 2018Research and Development MSD, Merck, NHS, NICE, keytruda, pharma
UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
